




RealRate

PHARMACEUTICAL 2022

Monopar Therapeutics
Rank 122 of 471



The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Monopar Therapeutics is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 363%, being 88% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	20,522	Assets	20,522
Cost of Goods Sold	0	Liabilities	1,581
Intangible Assets	0	Expenses	9,127
Liabilities, Current	0	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	18,941
Other Assets	0	Net Income	-9,103
Other Compr. Net Income	4.7	Comprehensive Net Income	-9,101
Other Expenses	0	BaseVar	15,629
Other Liabilities	1,581	ECR before LimitedLiability	291%
Other Net Income	24	Economic Capital Ratio	363%
Other Revenues	0		
Property and Equipment	0		
Research and Development	6,493		
Selling, General and Administrative Expense	2,634		